Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells

被引:55
作者
Timms, JF
White, SL
O'Hare, MJ
Waterfield, MD
机构
[1] Ludwig Inst Canc Res, London W1W 7BS, England
[2] UCL, Breast Canc Lab, Dept Surg, Royal Free & Univ Coll Med Sch, London W1W 7EJ, England
关键词
ErbB-2; cell cycle; cdk inhibitors; cdk2; luminal epithelial;
D O I
10.1038/sj.onc.1205847
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most breast cancers arise from luminal epithelial cells and 25-30% of these tumours overexpress the ErbB-2 receptor. Herein, a non-transformed, immortalized cell system was used to investigate the effects of ErbB-2 overexpression in luminal epithelial cells. The phenotypic consequence of ErbB-2 overexpression is a shortening of the G1 phase of the cell cycle and early S phase entry, which leads to hyperproliferation. We show that this effect was mediated through the up-regulation of cdk6 and cyclins D1 and E, and enhanced degradation and relocalization of P27(Kip1). These changes were effected predominantly through enhanced MAPK signalling, resulting in cdk2 hyperactivation. PI3K signalling also participated in cell cycle progression, since PI3K and MAPK coordinately regulated changes in cyclin D1 and cdk6 expression. Cdk4 activity was not required for cell cycle progression in these cells, and was constitutively inhibited through its association with p16(INK4A). MAPK-dependent induction of p21(Cip1) was also necessary for G1 phase progression, although its degradation by the proteasome was required for S phase entry. These data provide new insights into the complex molecular mechanisms underlying mitogenic cell cycle control in luminal epithelial cells, the cell type relevant to primary breast cancer, and show how ErbB-2 overexpression subverts this normal control.
引用
收藏
页码:6573 / 6586
页数:14
相关论文
共 65 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] Proteasome inhibition: a new strategy in cancer treatment
    Adams, J
    Palombella, VJ
    Elliott, PJ
    [J]. INVESTIGATIONAL NEW DRUGS, 2000, 18 (02) : 109 - 121
  • [3] Amati B., 1998, FRONT BIOSCI, V3, pd250, DOI DOI 10.2741/A239
  • [4] [Anonymous], 1988, Antibodies: A Laboratory Manual
  • [5] CYCLIN D1 PROTEIN EXPRESSION AND FUNCTION IN HUMAN BREAST-CANCER
    BARTKOVA, J
    LUKAS, J
    MULLER, H
    LUTZHOFT, D
    STRAUSS, M
    BARTEK, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (03) : 353 - 361
  • [6] A SINGLE AUTOPHOSPHORYLATION SITE CONFERS ONCOGENICITY TO THE NEU/ERBB-2 RECEPTOR AND ENABLES COUPLING TO THE MAP KINASE PATHWAY
    BENLEVY, R
    PATERSON, HF
    MARSHALL, CJ
    YARDEN, Y
    [J]. EMBO JOURNAL, 1994, 13 (14) : 3302 - 3311
  • [7] Regulation of p21cip1 expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase
    Bottazzi, ME
    Zhu, XY
    Böhmer, RM
    Assoian, RK
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 146 (06) : 1255 - 1264
  • [8] Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity
    Busse, D
    Doughty, RS
    Ramsey, TT
    Russell, WE
    Price, JO
    Flanagan, WM
    Shawver, LK
    Arteaga, CL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (10) : 6987 - 6995
  • [9] Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer
    Catzavelos, C
    Bhatacharya, N
    Ung, YC
    Wilson, JA
    Roncari, L
    Sandhu, C
    Shaw, P
    Yeger, H
    MoravaProtzner, I
    Kapusta, L
    Franssen, E
    Pritchard, KI
    Slingerland, JM
    [J]. NATURE MEDICINE, 1997, 3 (02) : 227 - 230
  • [10] The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
    Cheng, MG
    Olivier, P
    Diehl, JA
    Fero, M
    Roussel, MF
    Roberts, JM
    Sherr, CJ
    [J]. EMBO JOURNAL, 1999, 18 (06) : 1571 - 1583